New clinical trial data on orforglipron reveals a biological ceiling that every person on GLP-1 medications needs to understand. I’m breaking down the ATTAIN-MAINTAIN trial findings, explaining what the 15% threshold means for long-term weight management, and identifying exactly who is — and isn’t — a strong candidate for the transition to the Ozempic pill.

The SURMOUNT MAINTAIN trial has delivered the most compelling evidence yet that obesity requires long-term management — not a finish line. New data reveals exactly what happens to your results at every dose decision, and the numbers make the choice undeniable.

Retatrutide is a triple-action therapy targeting GLP-1, GIP, and glucagon receptors simultaneously — a fundamentally different design from current treatments. Early clinical data reveals significant liver-fat reductions and an unexpected paradox: a receptor long assumed to raise blood sugar instead helps mobilize stored fat and support resting metabolism.